Abstract: Disclosed is a battery swap station. The battery swap station includes a battery swap operation room and a battery compartment. The battery swap operation room is used for battery replacement of an electrical apparatus. The battery compartment is used for storing and charging batteries, the battery compartment is provided with a communicating opening, the communicating opening communicates the battery swap operation room with the battery compartment, and the communicating opening is used for batteries to get in and out of the battery compartment. By providing the communicating opening, the batteries can conveniently move between the battery swap operation room and the battery compartment, the movement distance of the batteries between the battery swap operation room and the battery compartment is shortened, the process time of the battery swap work is reduced, and the battery swap efficiency is improved. Further provided is a battery swap method.

Abstract: A battery swapping station includes: a body internally provided with a battery storage area and a turnover channel both extending in a first direction and arranged side by side in a second direction. The battery storage area includes a plurality of storage positions sequentially distributed in a first direction and used for storing batteries, and an adjustment position located on one side of the plurality of storage positions in the first direction. The turnover channel is used for transferring the batteries at the storage positions. The first direction and the second direction are perpendicular to each other. The adjustment position and the turnover channel together form a battery adjustment area. A wall surface of the body in the first direction is provided with a battery access opening, and the battery access opening communicates with the battery adjustment area.

Abstract: A surge protection circuit includes a first surge protection device (SPD) including a first terminal coupled to a voltage potential and a second terminal. A second SPD includes a first terminal coupled to the voltage potential and a second terminal. A diode array includes a first plurality of diodes, each diode of the first plurality of diodes including an anode coupleable to a respective power line of an electronic circuit and a cathode coupled to the second terminal of the first SPD. The diode array also includes a second plurality of diodes, each diode of the second plurality of diodes including a cathode coupled to a respective power line of the electronic circuit and an anode coupled to the second terminal of the second SPD. The second terminal of the first SPD is further coupled to a common power bus of the electronic circuit.

Abstract: A lifting device for a battery swapping station and a battery swapping station comprises a driving mechanism, a lifting mechanism and a transmission mechanism. The lifting mechanism comprises a first and a second lifting assemblies, wherein the first and second lifting assemblies are arranged on two sides of the driving mechanism in a first direction and are used for lifting an electric device, the first direction being perpendicular to a direction in which the electric device is lifted. The transmission mechanism comprises a first transmission assembly and a second transmission assembly, wherein the first transmission assembly is connected to the driving mechanism and the first lifting assembly; the second transmission assembly is connected to the driving mechanism and the second lifting assembly; and by means of the first and second transmission assemblies, the driving mechanism drives the first and second lifting assemblies to move synchronously.

Abstract: The present invention relates to isolated and engineered human antibodies that specifically bind to at least one conformational (non-linear) epitope of HBsAg and neutralize hepatitis B virus infection, methods for producing the same, and uses thereof in treating human HBV infection.

Abstract: Generation of chimeric non-human animals hosting bat donor cells involves chimeric mice having bat cells that may be stably tolerated to provide a new platform technology in the general field of biology, and having application in the field of immunology related to virus-host interaction, cancer biology, autoimmunity, and the development of new drugs.

Abstract: Disclosed herein is a nanoparticle composition comprising nanoparticles formed from one of: a conjugate of dimeric epigallocatechin-3-O-gallate and hyaluronic acid; a conjugate of epigallocatechin-3-O-gallate and hyaluronic acid; or a epigallocate-chin-3-O-gallate-terminated hyaluronic acid conjugate; and an active agent or a pharmaceutically acceptable salt, solvate or prodrug 0thereof suitable to treat acute myeloid leukaemia, wherein the active agent is encapsulated in the nanoparticles.

Abstract: Generation of chimeric non-human animals hosting bat donor cells involves chimeric mice having bat cells that may be stably tolerated to provide a new platform technology in the general field of biology, and having application in the field of immunology related to virus-host interaction, cancer biology, autoimmunity, and the development of new drugs.

Abstract: This invention refers to a mouse for human hepatitis studies wherein the mouse has been injected with CD34+ stem cells and wherein the mouse is immunocompromised, as well as a method of manufacturing a mouse model comprising administering CD34+ stem cells as defined herein into an immunocompromised mouse as defined herein. The invention also refers to the use of a mouse as defined for testing the efficiency of putative anti-HBV or anti-HCV drugs or for characterizing changes in viral quasispecies during HBV or HCV infection.

Abstract: The invention is directed to a method of determining whether an agent causes immune toxicity in a human comprising administering the agent to a non-human mammal that has been engrafted with human hematopoietic stem cells (HSCs) and administered one or more human cytokines; and determining whether the agent causes immune toxicity in the non-human mammal. If the agent causes immune toxicity in the non-human mammal then the agent causes toxicity in a human. The invention is also directed to a method of determining whether administration of an agent causes cytokine release syndrome in an individual in need thereof comprising administering the agent to a non-human mammal that has been engrafted with HSCs and administered one or more human cytokines; and determining whether the agent causes cytokine release syndrome in the non-human mammal. If the agent causes cytokine release syndrome in the non-human mammal then the agent will cause cytokine release syndrome in the human.

Abstract: The embodiments of the present invention disclose a method, a device, and a system for controlling multichannel cascade between two media control servers. The method comprises: receiving a service request message; choosing a target channel among all the channels multichannel-cascaded with an opposite cascaded media control server according to the service request message and a preset channel usage rule; and sending information about the determined target channel to the opposite cascaded media control server so as to enable the opposite cascaded media control server to carry out code stream switching according to the information about the target channel. The method disclosed in the embodiments of the present invention saves cascaded channels and improves the utilization of cascaded channels, thereby saving channel resources.

Abstract: Provided herein are methods of reconstituting functional human blood cell lineages in a non-human mammal comprising introducing human hematopoietic stem cells (HSCs) and nucleic acid encoding one or more human cytokines into an immunodeficient non-human mammal. The non-human mammal is maintained under conditions in which the nucleic acid is expressed and the human HSCs differentiate into functional human blood cell lineages in the non-human mammal, thereby reconstituting functional human blood cell lineages in the non-human mammal. Also provided are methods of producing human antibodies directed against an immunogen in a non-human mammal, hybridomas that secrete the monoclonal antibodies as well as antibodies (e.g., polyclonal antibodies; monoclonal antibodies) produced by the B cells and non-human mammals produced by the methods.

Abstract: The embodiments of the present invention disclose a method, a device, and a system for controlling multichannel cascade between two media control servers. The method comprises: receiving a service request message; choosing a target channel among all the channels multichannel-cascaded with an opposite cascaded media control server according to the service request message and a preset channel usage rule; and sending information about the determined target channel to the opposite cascaded media control server so as to enable the opposite cascaded media control server to carry out code stream switching according to the information about the target channel. The method disclosed in the embodiments of the present invention saves cascaded channels and improves the utilization of cascaded channels, thereby saving channel resources.